The University of Manchester

Domainex Limited

Other

St Georges Hospital Medical School

St George's Hosptial Medical School

Gary Karl Newton

Mark Richard Stewart

Trevor Robert Perrior

Kerry Jenkins

Clive Robinson

David Ronald Garrod

Meriel Ruth Major

Jihui Zhang

Andrew Philip Crew

Arlindo Lucas Castelhano

An-Hu Li

Kevin James Doyle

Neil Anthony Pegg

Shazia Sadiq

John Fraser Keily

Chrystelle Marie Rasamison

Rehan Aqil

Rebekah Elisabeth Key

Anna Hopkins

Don Smyth

Imaad Saba

Graham Dawson

Saleh Ahmed

Graham Michael Wynne

Claire Thomas

Rebekah Elisabeth Beevers

Gabriel Negoita-giras

Stuart Richard Crosby

Meriel Ruth Mayor

The invention provides compounds of formula (I) wherein R is &#x2014;CHor &#x2014;CHCHand pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of diseases or disorders mediated by IKK, TBK1 and/or SIK2 mechanisms in a subject, for example cancer and inflammatory and tissue repair disorders. The invention also provides uses of the compounds of formula (I) and compositions containing them. (Formula (I)) 

5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as IKKE, TBK1 and/or SIK2 kinases inhibitors

C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKK&#x3b5; and/or TBK-1: in which: Rrepresents an aliphatic heterocyclyl group having 4, 5, 6 or 7 ring atoms, bonded to the phenyl group shown in formula I through a ring nitrogen atom, and optionally substituted by one or more substituents defined in the Specification; Rrepresents a phenyl or heteroaryl group which is optionally substituted by one or more substituents defined in the Specification; and each of Rand Rindependently represents a hydrogen atom or a Calkyl group. 

Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as 'PVA compounds'), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy. 

Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use

The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as 'PVA compounds'), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Compounds represented by Formula (I):or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1 isR2 isand R3 is Calkyl, are useful in the treatment of cancer.

(2-carboxamido)(3-amino)thiophene compounds

Growing community of inventors

Cambridge, United Kingdom

Gary Karl Newton